regeneron is a buy but you have to be willing to accept the fact there are some price risks.t, ladies and gentlemen, is the conclusion of the lightning round. [ buzzer ] >> announcer: the lightning round is sponsored by td ameritrade. >>> good evening, jim, thaw for taking my call. after taking a tour of again necessary brewery at the end of the tour i found out that they were owned by diagio. >> i went to that same guinness and i happen to have a diploma for pouring and it's also my wife's screen safer. she got -- she had magna cum laude pour. that was the first course i have taken since harvard and it was much harder. >> how about this check that cbs is priegt for march madness, extension for eight years. >> until 2032. >> the joke was are we going to be watching it on vr, is it going to look like you're court side from home? >> you will just be a box watching it. >> i'm a bot? >> you will be marching around with those goggles on. >> yeah, these are now the short sellers are coming. >> this is the part in the show where i talk about the rise of artificial intelligence and m

we'll have to see whether or not regeneron can recover from today's many routes. betty: thank you.nk it is about time we talk about vegas. mark: that is right, making big -- betty: that is right, making big vets -- big bets, rolling the dice. $1 billion more than in its initial public offering. shares are higher. up about 7%. it priced 50 million shares at $21 apiece. the top end of the range. casinon interest in resorts like the mandalay bay, the mirage. we have not had that many ipo's this year. joining us from the floor is an jim growth property ceo james seward. so, james, you can get chance, did your ipo. it has been a dry pipe line. how do you feel? : i cannot be more proud to be associated with this company and the people in it. the reception we have gotten has been overwhelming, and i feel great. betty: so, who are your investors? are they investors that are traditionally in reits, or are they more diverse -- who are they exactly? broad sett: we have a of investors. it would include reit investors, funds, people that own and jim resort stock -- a nice, broad group. betty: j

regeneron is the best performer today.ir drug to treat a serious skin condition met its goal in two late stage trials. that clears the trials to regulatory approval. it's important for regeneron eyees on ilia, it's treatment. it is looking to diversify into other areas. that is why see such a big gain in the stock today. it's a member of the nasdaq biotech index, which for the week is up nearly 5%. that is its best weekly performance going back to september. i was looking at some other best performers. it has to do with drug approvals or positive news on particular products. all the biopharmaceuticals had about a 62% gain on the first day of the week, that is after the company said its experiment till confusion to prevent migraines that the main goal of a mid-stage trial. older pharmaceutical has been up -- alder pharmaceuticals is up after approval by the fda. that stock is up 41% on the week. you in macro news aside, have some specific stories driving. matt: actual news moving markets. thanks, julie. lisa: tesla's model

how about regeneron we followed since it was a $5 stock.here are fabulous stocks thanks to the macular degeneration drug. since last summer the stock was put through the meat grinder along with the rest of the group. take a gander at the daily chart. okay? like the others, regeneron made a double bottom which keeps coming up in february and march. it looks to be breaking up to the upside. last week it took out a prior high at 384. the fact it bounced after it test ed the floor of support between 331 and 338 makes it more confident on a pull back. as long as it holds out above the march 17 low of 348 she believes it can keep high. she wouldn't be surprised if the stock rallies to 499506. that would be a hundred point gain from where it trades. i like this. dove tails nicely with the new drug. it went up big last week. now celgene, host of very exciting new products in the pipeline. brodin didn't spot anything compelling on the chart. she went to a 30 minute chart where each tick is half an hour of trading. she sees a nice bullish pattern and

. >>> drugmakers regeneron said the new drug for a specific type of eczema has met its targets in two trials. shares spiked 12% to 405.25. shares of sanafee rose to 40.33. >>> four airlines saw shares take a hit after one analyst downgraded the companies. deutsche bank lowered its ratings of american, delta, united, continental, and hawaii saying the slow-down in corporate profits could result in less demand for business travel. shares of american dropped more than 3.5% to 39.52. delta down about the same, 47.01. united off 5% at 56.72. and hawaiian fell more than 2% to 46 even. >>> federal communications commission said it will not investigate netflix after the streaming video company admitted last week to deteriorating picture quality for at&t and verizon customers. the fcc said the matter was outside the agency's jurisdiction. today netflix shares up more than 3% at 105.70. >>> our market monitor guest is findin opportunity in small cap stocks. he says they're going to rise more than 25% this year. this is his first time joining us on the program. steven diniccolo, portfolio manage

regeneron. julie: the stock is up 11.5% at the moment.t does have to do with your skin or skin in general. you see the stock on the bloomberg. it's up 11.5%. eczema.s a type of the skin cleared. this is for people who have the most severe version of this particular illness. it has one blockbuster drug. it's an eye treatment. in accounted for 65% of the sales. regeneron has started working on some other drugs. we are looking at other biotech stocks. it's up 5.5%. this is going back to september. i want to point out some of the other performers on the week. this is the best performer on the week. that can't be right. guess we have a bit of a bug here. it's an experimental infusion to prevent main -- migraines. that happened earlier in the week. the stock surged. i can see looking at my terminal. now i am seen different stocks on the move. give me one more second. that is theick first one is see listed. of the parkinson's disease drug, it was reduced -- reviewed favorably by an fda committee. it should be up by 41% for the week. it looks lik

abigail: we have regeneron. the biotech giant is soaring.he primary endpoint in two separate studies. data and the results are pretty flawless without concerns around health or safety concerns. that's pretty decent. it could be a drug for the two companies. the stock is down sharply from its record peak last year. abigailhank you doolittle. let's check in with the news. ramy: we've had to belgium and the prime minister and key cabinet members met to discuss when the bomb damaged airport can reopen. authorities are hoping that passenger flights can resume soon after a terror attack killed 30 people. the police unions are checking passengers at the check in area. greece is pressing ahead with a chance to send refugees back to turkey. they will allow those returns to start asking as monday. refugees who landed after march 20 would be put on boats and sent back to turkey. kicks u k, a minimum wage in. the economy will lose workers and gain efficiency. that is the forecast. david cameron's government has boosted the minimum wage to $10.35 per hou

again, regeneron has so many products. people just regard it as one company.'t say enough about how good that company is. cholesterol drug is good, too. very smart company. >> stock still down 22%. >> biotech. biotech. valeant. while you were away, valeant went down. >> really? >> it went down. >> day one of my vacation it was mike pearson, see you later. then we had mario coming back for starwood. >> you missed nothing. >> i missed nothing. you have to take your vacations. >> it's like a city bus, there will be another. >> there will be one more. one question to ask in the fallout from starwood what do you do next time there's an incoming bid from a chinese company? how do you approach it as a potential seller? anbang's decision and lack of transparency as to why they chose to walk away after bidding, bidding again, seemingly having a deal yet again, is giving people pause in the m&a community, it's fair to say. that may be the important -- we can talk about marriott, the virtues of the deal, the billion more they have to pay. next time there's an inbound off

just for fun, best and worst performing stocks this week in the s&p, regeneron and rlunima, the worstthe s&p index is l allergan. >> oil stocks? >> this morning you were for first 20 minutes of the day, oil was down on the points and we were down also. then two things happened that were important, oil began to stabilize below 37 and outcome the ism after five negative months we were above 50, minus 100, up to 110. >> not just oil, the dollar a little decoupling, little bit of dollar strength in the last few days and normally that's a toxic mix. strong dollar has been a real problem for stocks in the past and wasn't today. i agree the ism was the turning point for the market. broader market managed to eek out small gains. >> when do we care about earnings? >> we're going to start to care about earnings shortly. as i've said earlier this week, that will mean that the corporate buybacks will be standing aside. that will be an important prop for this market that will not be around for the next three weeks or so. >> can we point out the vix has collapsed? now remember the fed was a major c

sanofi and regeneron say their experimental drug have proven positive. if cleared by the fda, it would be the first approved systemic treatment for the skin condition. >>> boeing has won a $326 million contract from the u.s. air force to build 15,000 smart bomb kits. the kit adds precision guidance to conventional bombs. the contract also covers technical and field support. >>> american airlines is dropping its policy of allowing customers to hold a reservation for 24 hours without paying. instead, customers who buy a ticket will have 24 hours to cancel it without being charged, which is already standard at other u.s. airlines. the switch goes into effect today for tickets bought over the phone. both policies much better than you get for european airlines. >> are they? really? >>> when we come back, happy birthday, apple. the tech giant turning 40 today. have a look at what the firm has achieved. 1 billion active apple devices in the world. >>> and our twitter and facebook question of the day. what would you wait in line for? the tesla model 3, as we jus

. >> can we talk about regeneron? >> dermatological. >> ceos of john deere, u.s.el and blackberry, we'll go to a break and be back with more. ok team, what if 30,000 people download the new app? we're good. okay... what if a million people download the new app? we're good. five million? good. we scale on demand. hybrid infrastructure, boom. ok. what if 30 million people download the app? we're not good. we're total heroes. scale on demand with the number one company in cloud infrastructure. - diversity isn't just important for your financial portfolio. it's also important for your life. celebrating, welcoming, and surrounding yourself with people of all kinds is an investment in both you and your community, and we're all the richer for it. >>> you know the selfie stick? they're everywhere. t-mobile has invented the hands-free -- this is breaking news. >> john ledger coming up with a device that is -- it's brilliant. verizon and at&t should be worried more than ever. look at this. look how useful this is. >> you don't need to use your hands. >> you can't see anythi

regeneron saying their treatment was highly effective in two large trials with no serious side effectslan to seek u.s. approval for the injectable drug. shares up by 13% so far on the day. back over to you, tyler. >>> oil tanking on comments from saudi prince -- prices set to close. the final trades will be next. >>> do you really need to wear a business suit anymore? or are hoodies becoming acceptable even in a bisseting said the g business setting said the guy with the suit. you got some hoodies? tweet us at "power lunch." #sui #suitsvshoodies. over the last 25 years, i've researched more than 450 financial products. i found that one of the best-kept secrets to help you plan for your retirement is the home equity conversion mortgage. it's a line of credit for homeowners age 62 or older. and it's offered by a company you can trust one reverse mortgage, a quicken loans company! no monthly mortgage payments are required and the money available to you increases every year. for example, if your 100,000 dollar line of credit remains untouched, it could increase to 300,000 or more, years la

regeneron shares are trading higher after it's -- growth concerns on its eye care treatment.erned about changes for coverage which may preface cheaper treatment. , coke is another one and tupperware. abbott labs, you can see right now trading over a third of a percent. down -- it didg not beat by enough on the revenue side or raise outlook. tupperware trading down three and two thirds percent. jon: the nasdaq down by roundabout seven points. abigail doolittle at the nasdaq with a look at movers in early trading. abigail: one stock moving against nasdaq come at dish network. stock is higher after the company reported a strong first quarter. in increase in streaming subscribers that more than offset a loss in the satellite subscribers. companyffett thinks the possibly satellite business could way a downtrend in the stock chart. suggestions that moffett could prove to be right. a price target of $40 per share. one stock that has been volatile in the first few minutes of trading on earnings, intel. 1% range after the company reported an in-line first quarter announced in an 11% w